Cellectar Biosciences, Inc. Impact of Restatement on Earnings Per Share, Basic (Deprecated 2020-01-31)
Cellectar Biosciences, Inc. (CLRB) reported Impact of Restatement on Earnings Per Share, Basic (Deprecated 2020-01-31) of $0.78 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-21.
Discontinued › Income Statement › Earnings Per Share
us-gaap:ImpactOfRestatementOnEarningsPerShareBasic · last filed 2018-03-21
- Cellectar Biosciences, Inc. impact of restatement on earnings per share, basic (deprecated 2020-01-31) for fiscal 2017 was $0.78.
USD
| Period end | Impact of Restatement on Earnings Per Share, Basic (Deprecated 2020-01-31) 12 month |
|---|---|
| 2017-12-31 | $0.78 10-K · filed 2018-03-21 |
USD/shares
| Period end | Impact of Restatement on Earnings Per Share, Basic (Deprecated 2020-01-31) 12 month |
|---|---|
| 2017-12-31 | $0.78 10-K · filed 2018-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |